The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 10. (Cancelled)

11. (Previously Presented): A compound of formula I



(I)

wherein

Y_1 means a hydrogen atom, a hydroxyl group, an alkanoyloxy group with 1 to 12 C atoms or an aroyloxy group,

Y_2 means a hydrogen atom or an alkanoyl group with 1 to 12 C atoms or an aroyl group,

R_1 and R_2 each mean a hydrogen atom or together an exocyclic methylene group,

R_3 and R_4, independently of one another, mean a hydrogen atom, a chlorine or fluorine atom, an alkyl group with 1 to 4 carbon atoms, or together form a methylene group, or together with quaternary carbon atom 20 form a 3- to 7-membered, saturated or unsaturated carbocyclic ring,

Q means a straight-chain or branched carbon unit with up to 10 carbon atoms, which at any position can have hydroxyl groups, in α- or β-position, which in turn can be etherified or esterified, keto groups, amino groups or halogen atoms,

R_5 and R_6 together with carbon atom 25 mean a 3- to 7-membered, saturated or unsaturated carbocyclic ring,

Z means a five- or six-membered carbocyclic ring which can be saturated, unsaturated or aromatic, and which can be substituted by one or more alkyl chains, which can be straight-

chain or branched, saturated or unsaturated, and optionally interrupted by oxa, thia, aza, sulfoxide or sulfo groups or substituted by hydroxy groups or halogen atoms, wherein if Z is phenyl, R_5 and R_6 together with carbon atom 25 form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring.

12. (Previously Presented): A compound according to claim 11, wherein R_5 and R_6 together with carbon atom C-25 means a cyclopropyl ring.

13. (Previously Presented): A compound according to claim 11, wherein Q is hydroxymethyl or carbonylmethyl group.

14. (Previously Presented): A compound according to claim 11, wherein the compound antagonizes the action of calcitriol in HL 60 cells.

15. (Previously Presented): A compound according to claim 11, wherein Y_1 is acetyloxy, propionyloxy, butyryloxy or benzoyloxy.

16. (Previously Presented): A compound according to claim 11, wherein Y_2 is acetyl, propionyl, butyryl or benzoyl.

17. (Previously Presented): A compound according to claim 11, wherein R_3 is H and R_4 is methyl.

18. (Previously Presented): A compound according to claim 11, wherein R_3 is methyl and R_4 is H.

19. (Previously Presented): A compound according to claim 11, wherein R_3 is F and R_4 is methyl.

20. (Previously Presented): A compound according to claim 11, wherein R_3 is methyl and R_4 is F.

21. (Previously Presented): A compound according to claim 11, wherein R_3 and R_4 together form a methylene group or together with tertiary carbon atom 20 form a cyclopropyl group.

22. (Previously Presented): A compound according to claim 11, wherein Q is an unsubstituted, unbranched alkylene having 1-3 carbon atoms.

23. (Previously Presented): A compound according to claim 11, wherein Q is hydroxymethylene in which the hydroxy group is in the α or β position.

24. (Previously Presented): A compound according to claim 11, wherein Q is -CH(OH)-CH_2- or -CH(OH)-CH_2-CH_2- in which, in each case, the hydroxy group is in the α or β position.

25. (Previously Presented): A compound according to claim 11, wherein R_5 and R_6 together with carbon atom C-25 form a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group.

26. (Previously Presented): A composition comprising at least one compound according to claim 11 and a pharmaceutically compatible vehicle.

27. (Currently Amended): A method of treating a patient suffering from ~~for~~ hyperprolifierative diseases of the skin selected from psoriasis, acne, and ichthyosis, tumor diseases selected from tumors of the intestines, carcinomas of the breast, lung tumors, prostate carcinomas, and leukemias, ~~and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, AIDS, atopic skin conditions, secondary hyperparathyroidism, renal osteodystrophia,~~ senile osteoporosis, steroid-induced osteoporosis, and/or ~~and~~ postmenopausal osteoporosis, ~~diabetes mellitus type II, and/or degenerative diseases of the peripheral and central nervous system~~ said method comprising:

administering to said patient a compound ~~composition~~ according to claim 11.

28. (Cancelled):

29. (Cancelled):

30. (Cancelled):

31. (Previously Presented): A method according to claim 27, wherein said compound is administered to said patient in an amount of 0.1 μg/day - 1000 μg/day.

32. (Cancelled):

33. (Previously Presented): A process for the production of a compound according to claim 11, said process comprising:

providing a compound of general formula II



II

wherein

Y'_1 means a hydrogen atom or a protected hydroxy group and

Y'_2 means a hydroxy protective group,

R_1 and R_2 each mean a hydrogen atom or together an exocyclic methylene group,

R_3 and R_4, independently of one another, mean a hydrogen atom, a chlorine or fluorine atom, an alkyl group with 1 to 4 carbon atoms, or together form a methylene group,

or together with quaternary carbon atom 20 form a 3- to 7-membered, saturated or unsaturated carbocyclic ring,

Q means a straight-chain or branched carbon unit with up to 10 carbon atoms, which at any position can have hydroxyl groups, in α- or β-position, which in turn can be etherified or esterified, keto groups, amino groups or halogen atoms,

R_5 and R_6 together with carbon atom 25 mean a 3- to 7-membered, saturated or unsaturated carbocyclic ring, and

Z' means a five- or six-membered carbocyclic ring which can be saturated, unsaturated or aromatic, and which can be substituted by one or more alkyl chains, which can be straight-chain or branched, saturated or unsaturated, and optionally interrupted by oxa, thia, aza, sulfoxide or sulfo groups or substituted by hydroxy groups or halogen atoms, wherein if Z' is phenyl, R_5 and R_6 together with carbon atom 25 form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring; and

reacting the compound by simultaneous or successive cleavage of the hydroxy protective groups and optionally by partial or complete esterification(s) or etherification(s) of free hydroxy groups.

34. (Previously Presented): A compound selected from:

(5Z,7E,22E)-(1S,3R,24R)-25-phenyl-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-phenyl-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-methylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-methylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-ethylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-ethylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-propylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-propylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-butylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-butylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(4-pentylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(4-pentylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-methylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-methylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-ethylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-ethylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-propylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-propylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-butylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-butylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-(3-pentylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24S)-25-(3-pentylphenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-[4-(1-methylethyl)phenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol

(5Z,7E,22E)-(1S,3R,24S)-25-[4-(1-methylethyl)phenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,

(5Z,7E,22E)-(1S,3R,24R)-25-[3-(1-methylethyl)phenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol,and

(5Z,7E,22E)-(1S,3R,24S)-25-[3-(1-methylethyl)phenyl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol.

35. (Currently Amended): A method according to claim 27, wherein said ~~of treating a~~ patient is suffering from a hyperprolifierative disease of the skin selected from psoriasis, acne, and ichthyosis~~, comprising administering to said patient a composition according to claim 11~~.

36. (Currently Amended): A method according to claim 27, wherein said ~~of treating a~~ patient is suffering from ~~a tumor disease or a precancerous stage of a tumor, selected from~~ tumors of the intestines, carcinomas of the breast, lung tumors, prostate carcinomas, or leukemias~~, T-cell lymphomas, melanomas, Batazell Larzin, squamous carcinoma, actinic keratoses, cervix dysplasias, and metastasizing tumors, said method comprising administering to said patient a composition according to claim 11~~.

37. (Cancelled):

38. (Cancelled):

39. (Cancelled):

40. (Cancelled):

41. (Currently Amended): A method according to claim 27, wherein said ~~of treating a~~ patient is suffering from senile osteoporosis, postmenopausal osteoporosis, or steroid-induced osteoporosis~~, comprising administering to said patient a composition according to claim 11~~.

42. (Cancelled):